Centrient Pharmaceuticals
Greenhouse gas emissions & sustainability report data
Figures are as stated in the company's own report and may use different boundaries, units or methods (for example market-based vs location-based Scope 2), so compare with care.
Renewable Energy
25% (2023, compared to 2015 baseline)
of total energy
📈 Emissions by Report Period
| Report period | Headline emissions figure reported |
|---|---|
| 2018-01 to 2019-12 | 328.7K tCO2e/year (Scope 1 & 2) |
Each row is the headline figure extracted from a different report; scope coverage and methodology can change between years.
✅ Reported Environmental Achievements
- 97% of waste repurposed (compared to 2021 baseline)
- 10% water consumption reduction (compared to 2021 baseline)
- 25% electricity sourced from renewable sources (compared to 2015 baseline)
- 46.2% absolute reduction in scope 1 and 2 greenhouse gas emissions by 2031 (target)
- 27.5% absolute reduction in scope 3 greenhouse gas emissions by 2031 (target)
🎯 Climate & Sustainability Targets
🔜 Short-term
- 5% reduction in water consumption intensity by 2030
- R&D projects pass Sustainability assessment (2025)
- Sites and suppliers compliant with AMR IA Common Manufacturing Framework and Predicted No-Effect Concentration targets
- High level of employee engagement - in top 10% for our industry (2025)
- 50% gender balance in senior management roles (2025)
📅 Medium-term
- Source 50% renewable electricity by 2030
- Increasing access of our lifesaving antibiotics to 2 billion patients by 2030
- 90% of waste repurposed and landfill only if no viable alternative available by 2030
🔭 Long-term
- 46.2% absolute reduction in scope 1 and 2 GHG emissions by 2031
- 27.5% absolute reduction in scope 3 GHG emissions by 2031
- 50,000+ lives touched by Centrient global community programme annually by 2030
🌱 ESG Focus Areas
EnvironmentalSocialGovernanceAntimicrobial Resistance (AMR)